Genetic polymorphism of thiopurine S-methyltransferase: Molecular mechanisms and clinical importance

Pharmacology

Volumn 61, Issue 3, 2000, Pages 136-146

  Krynetski, Eugene Y ^a   Evans, William E ^a,b  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

Genotyping; Mercaptopurine; Methyltransferase; Thioguanine

Indexed keywords

6 MERCAPTOPURINE DERIVATIVE; ANTIINFLAMMATORY AGENT; ANTINEOPLASTIC AGENT; AZATHIOPRINE; CELL DNA; DRUG METABOLIZING ENZYME; MERCAPTOPURINE; METHYLTRANSFERASE; THIOPURINE S METHYLTRANSFERASE; TIOGUANINE; UNCLASSIFIED DRUG;

ALLELE; AUTOSOMAL DOMINANT INHERITANCE; CODOMINANCE; DNA DETERMINATION; DRUG INDUCED DISEASE; DRUG METABOLISM; ENZYME ACTIVITY; ETHNIC DIFFERENCE; GENETIC POLYMORPHISM; GENOTYPE; HETEROZYGOSITY; HUMAN; PHARMACOGENETICS; PRIORITY JOURNAL; REVIEW;

EID: 0033828949     PISSN: 00317012     EISSN: None     Source Type: Journal    
DOI: 10.1159/000028394     Document Type: Review

References (72)

1. Remy CN: Metabolism of thiopyrimidines and thiopurines: S-methylation with S-adenosylmethionine transmethylase and catabolism in mammalian tissues. J Biol Chem 1963;238: 1078-1084.
2. Remy CN: Ribonucleotides and ribonucleosides as methyl acceptors for S-adenosylmethionine: (Amino- and thio-)purine methyltransferases. Biochim Biophys Acta 1967;138: 258-275.
3. Woodson LC, Weinshilboum RM: Human kidney thiopurine methyltransferase. Purification and biochemical properties. Biochem Pharmacol 1983;32:819-826.
4. Krynetski EY, Evans WE: Pharmacogenetics as a molecular basis for individualized drug therapy: The thiopurine S-methyltransferase paradigm. Pharm Res 1999;16:342-349.
5. Woodson LC, Ames MM, Selassie CD, Hansch C, Weinshilboum RM: Thiopurine methyltransferase. Aromatic thiol substrates and inhibition by benzoic acid derivatives. Mol Pharmacol 1983;24:471-478.
6. Ames MM, Selassie CD, Woodson LC, Van Loon JA, Hansch C, Weinshilboum RM: Thiopurine methyltransferase: Structure-activity relationships for benzoic acid inhibitors and thiophenol substrates. J Med Chem 1986;29:354-358.
7. Deininger M, Szumlanski CL, Otterness DM, Van Loon J, Ferber W, Weinshilboum RM: Purine substrates for human thiopurine methyltransferase. Biochem Pharmacol 1994;48: 2135-2138.
8. Krynetski EY, Krynetskaia NF, Yanishevski Y, Evans WE: Methylation of mercaptopurine, thioguanine, and their nucleotide metabolites by heterologously expressed human thiopurine S-methyltransferase. Mol Pharmacol 1995;47: 1141-1147.
9. Szumlanski CL, Weinshilboum RM: Sulphasalazine inhibition of thiopurine methyltransferase: Possible mechanism for interaction with 6-mercaptopurine and azathioprine. Br J Clin Pharmacol 1995;39:456-459.
10. Lysaa R, Giverhaug T, Libaek Wold H, Aarbakke J: Inhibition of human thiopurine methyltransferase by furosemide, bendroflumethiazide, and trichlormethiazide. Eur J Clin Pharmacol 1997;49:393-396.
11. Lewis LD, Benin A, Szumlanski CL, Otterness DM, Lennard L, Weinshilboum RM, Nierenberg DW: Olsalazine and 6-mercaplopurine-related bone marrow suppression: A possible drug-drug interaction. Clin Pharmacol Ther 1997;62:464-475.
12. McLeod HL, Krynetski EY, Wilimas JA, Evans WE: Higher activity of polymorphic thiopurine S-methyltransferase in erythrocytes from neonates compared to adults. Pharmacogenetics 1995;5:281-286.
13. Evans WE, Horner M, Chu YQ, Kalwinsky D, Roberts WM: Altered mercaptopurine metabolism, toxic effects, and dosage requirement in a thiopurine methyltransferase-deficient child with acute lymphocytic leukemia. J Pediatr 1991;119:985-989.
14. Leonard L, Gibson BE, Nicole T, Lilleyman JS: Congenital thiopurine methyltransferase deficiency and 6-mercaptopurine toxicity during treatment for acute lymphoblastic leukaemia. Arch Dis Child 1993;69:577-579.
15. Lennard L, Van Loon JA, Weinshilboum RM: Pharmacogenetics of acute azathioprine toxicity: Relationship to thiopurine methyltransferase genetic polymorphism. Clin Pharmacol Ther 1989;46:149-154.
16. Schutz E, Gummert J, Mohr F, Oellerich M: Azathioprine-induced myclosuppression in thiopurine methyltransferase deficient heart transplant recipient (letter) (see comments). Lancet 1993;341:436-436.
17. Relling MV, Lui Q, Pui CH, Evans WE: Are patients with intermediate TPMT activity (e.g. heterozygous genotypes and phenotypes) at intermediate risk of thiopurine hematopoietic toxicity? Second Thiopurine Symposium, Hamburg, 1996, abstr.
18. Aarbakke J, Janka-Schaub G, Elion GB: Thiopurine biology and pharmacology. Trends Pharmacol Sci 1997;18:3-7.
19. Relling MV, Rubnitz JE, Rivera GK, Boyett JM, Hancock ML, Felix CA, Kun LE, Walter AW, Evans WE, Pui CH: High incidence of secondary brain tumours after radiotherapy and antimetabolites (sec comments). Lancet 1999;354:34-39.
20. Relling MV, Yanishevski Y, Nemec J, Evans WE, Boyett JM, Behm FG, Pui CH: Etoposide and antimetabolite pharmacology in patients who develop secondary acute myeloid leukemia. Leukemia 1998;12:346-352.
21. Bo J, Schroder H, Kristinsson J, Madsen B, Szumlanski C, Weinshilboum R, Andersen JB, Schmiegelow K: Possible carcinogenic effect of 6-mercaptopurine on bone marrow stem cells: Relation to thiopurine metabolism. Cancer 1999;86:1080-1086.
22. Lennard L, Lilleyman JS: Variable mercaptopurine metabolism and treatment outcome in childhood lymphoblastic leukemia [published erratum appears in J Clin Oncol 1990;8:567]. J Clin Oncol 1989;7:1816-1823.
23. Lennard L, Lilleyman JS, Van Loon J, Weinshilboum RM: Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia. Lancet 1990;336:225-229.
24. McLeod HL, Miller DR, Evans WE: Azathioprine-induced myelosuppression in thiopurine methyltransferase deficient heart transplant recipient (letter; comment). Lancet 1993;341: 1151-1151.
25. Chocair PR, Duley JA, Simmonds HA, Cameron JS: The importance of thiopurine methyltransferase activity for the use of azathioprine in transplant recipients. Transplantation 1992; 53:1051-1056.
26. Weinshilboum RM, Sladek SL: Mercaptopurine pharmacogenetics: Monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Hum Genet 1980;32:651-662.
27. McLeod HL, Lin JS, Scott EP, Pui CH, Evans WE: Thiopurine methyltransferase activity in American white subjects and black subjects. Clin Pharmacol Ther 1994;55:15-20.
28. Krynetski EY, Sehuetz JD, Galpin AJ, Pui CH, Relling MV, Evans WE: A single point mutation leading to loss of catalytic activity in human thiopurine S-methyltransferase. Proc Natl Acad Sci USA 1995;92:949-953.
29. Tai HL, Krynetski EY, Yates CR, Loennechen T, Fessing MY, Krynetskaia NF, Evans WE: Thiopurine S-methyltransferase dificiency: Two nucleotide transitions define the most prevalent mutant allele associated with loss of catalytic activity in Caucasians. Am J Hum Genet 1996;58:694-702.
30. Szumlanski C, Otterness D, Her C, Lee D, Brandriff B, Kelsell D, Spurr N, Lennard L, Wieben E, Weinshilboum R: Thiopurine methyltransferase pharmacogenetics: Human gene cloning and characterization of a common polymorphism. DNA Cell Biol 1996;15:17-30.
31. Otterness D, Szumlanski C, Lennard L, Klemetsdal B, Aarbakke J, Park-Hah JO, Iven H, Schmiegelow K, Branum E, O'Brien J, Weinshilboum R: Human thiopurine methyltransferase pharmacogenetics: Gene sequence polymorphisms. Clin Pharmacol Ther 1997;62:60-73.
32. Otterness DM, Szumlanski CL, Wood TC, Weinshilboum RM: Human thiopurine methyltransferase pharmacogenetics. Kindred with a terminal exon splice junction mutation that results in loss of activity. J Clin Invest 1998; 101:1036-1044.
33. Loennechen T, Yates CR, Fessing M, Relling MV, Krynetski EY, Evans WE: Isolation of a human thiopurine S-methyltransferase (TPMT) complementary DNA with a single nucleotide transition A719G (TPMT*3C) and its association with loss of TPMT protein and catalytic activity in humans. Clin Pharmacol Ther 1998;64:46-51.
34. Spire-Vayron de la Moureyre C, Debuysere H, Sabbagh N, Marez D, Vinner E, Chevalier ED, Lo Guidice JM, Broly F: Detection of known and new mutations in the thiopurine S-methyltransferase gene by single-strand conformation plymorphism analysis. Human Mutation 1998; 12:177-185.
35. Hon YY, Fessing M, Pui CH, Relling MV, Krynetski EY, Evans WE: Polymorphism of the thiopurine S-methyltransferase gene in African-Americans. Hum Mol Genet 1999;8:371-376.
36. Yates CR, Krynetski EY, Loennechen T, Fessing MY, Tai HL, Pui CH, Relling MV, Evans WE: Molecular diagnosis of thiopurine S-methyltransferase deficiency: genetic basis for azathioprine and mercaptopurine intolerance (see comments). Ann Intern Med 1997;126:608-614.
37. Spire-Vayrone de la Moureyre C, Debuysere H, Sabbagh N, Marez D, Vinner E, Chevalier ED, Lo Guidice JM, Broly F: Detection of known and new mutations in the thiopurine S-methyltransferase gene by single-strand conformation polymorphism analysis. Hum Mutat 1998;12: 177-185.
38. Honchel R, Aksoy IA, Szumlanski C, Wood TC, Otterness DM, Wieben ED, Weinshilboum RM: Human thiopurine methyltransferase: Molecular cloning and expression of T84 colon carcinoma cell cDNA. Mol Pharmacol 1993;43:878-887.
39. Fessing M, Belkov VM, Krynetski EY, Evans WE: Molecular cloning and functional characterization of the cDNA encoding the murine thiopurine S-methyltransferase (TPMT). FEBS Lett 1998;424:143-145.
40. Hernandez JS, Van Loon JA, Otterness DM, Weinshilboum RM: Mouse thiopurine methyltransferase pharmacogenetics: Correlation of immunoreactive protein and enzymatic activity. J Pharmacol Exp Ther 1990;252:568-573.
41. Otterness DM, Weinshilboum RM: Mouse thiopurine methyltransferase pharmacogenetics: Biochemical studies and recombinant inbred strains. J Pharmacol Exp Ther 1987; 243:180-186.
42. Otterness DM, Keith RA, Weinshilboum RM: Thiopurine methyltransferase: Mouse kidney and liver assay conditions, biochemical properties and strain variation. Biochem Pharmacol 1985;34:3823-3830.
43. Weinshilboum RM, Adjei A, Johnson G, Otterness D: Thiopurine methyltransferase pharmacogenetics: inbred animal models, biochemical and molecular studies. Second Thiopurine Symposium, Hamburg, 1996, abstr.
44. Cournoyr B, Watanabe S, Vivian A: A tellurite-resistance genetic determinant from phytopathogenic pseudomonads encodes a thiopurine methyltransferase: Evidence of a widely-conserved family of methyltransferases. Biochim Biophys Acta 1998;1397:161-167.
45. Krynetski EY, Fessing MY, Yates CR, Sun D, Schuetz JD, Evans WE: Promoter and intronic sequences of the human thiopurine S-methyltransferase (TPMT) gene isolated from a human Pac1 genomic library. Pharm Res 1997; 14:1672-1678.
46. Krynetski EY, Tai HL, Yates CR, Fessing MY, Loennechen T, Schuetz JD, Relling MV, Evans WE: Genetic polymorphism of thiopurine S-methyltransferase: Clinical importance and molecular mechanisms. Pharmacogenetics 1996;6:279-290.
47. Lee D, Szumlanski C, Houtman J, Honchel R, Rojas K, Overhauser J, Wieben ED, Weinshilboum RM: Thiopurine methyltransferase pharmacogenetics: Cloning of human liver cDNA and a processed pseudogene on human chromosome 18q21.1. Drug Metab Dispos 1995;23:398-405.
48. Fessing M, Krynetski EY, Zambetti GP, Evans WE: Functional characterization of the human thiopurine S-methyltransferase (TPMT) gene promoter. Eur J Biochem 1998;256:510-517.
49. Spire-Vayron de la Moureyre C, Debuysere H, Mastain B, Vinner E, Marez D, Lo Guidice JM, Chevalier D, Brique S, Motte K, Colombel JF, Turck D, Noel C, Flipo RM, Pol A, Lhermitte M, Lafitte JJ, Libersa C, Broly F: Genotypic and phenotypic analysis of the polymorphic thiopurine S-methyltransferase gene (TPMT) in a European population. Br J Pharmacol 1998;125:879-887.
50. Spire-Vayron de la Moureyre C, Debuysere H, Fazio F, Sergent E, Bernard C, Sabbagh N, Marez D, Lo Guidice JM, D'halluin JC, Broly F: Characterization of a variable number tandem repeat region in the thiopurine S-methyltransferase gene promoter. Pharmacogenetics 1999;9:189-198.
51. Tai HL, Krynetski EY, Schuetz EG, Yanishevski Y, Evans WE: Enhanced proteolysis of thiopurine S-methyltransferase (TPMT) encoded by mutant alleles in humans (TPMT*3A, TPMT*2): Mechanisms for the genetic polymorphism of TPMT activity. Proc Natl Acad Sci USA 1997;94:6444-6449.
52. Ciechanover A, Schwartz AL: The ubiquitin-mediated proteolytic pathway: Mechanisms of recognition of the proteolytic substrate and involvement in the degradation of native cellular proteins. FASEB J 1994;8:182-191.
53. Olson TS, Dice JF: Regulation of protein degradation rates in eukaryotes. Curr Opin Cell Biol 1989;1:1194-1200.
54. Tai HL, Fessing MY, Bonten EJ, Yanishevsky Y, d'Azzo A, Krynetski EY, Evans WE: Enhanced proteasomal degradation of mutant human thiopurine S-methyltransferase (TPMT) in mammalian cells: Mechanism for TPMT protein deficiency inherited by TPMT*2, TPMT*3A, TPMT*3B or TPMT*C. Pharmacogenetics 1999;9:641-650.
55. Weinshilboum RM, Raymond FA, Pazmino PA: Human erythrocyte thiopurine methyltransferase: radiochemical microassay and biochemical properties. Clin Chim Acta 1978;85: 323-333.
56. Woodson LC, Dunnette JH, Weinshilboum RM: Pharmacogenetics of human thiopurine methyltransferase: Kidney-crythrocyte correlation and immunotitration studies. J Pharmacol Exp Ther 1982;222:174-181.
57. Lennard L, Singleton HJ: High-performance liquid chromatographic assay of the methyl and nucleotide metabolites of 6-mercaptopurine: Quantitation of red blood cell 6-thioguanine nucleotide, 6-thioinosinic acid and 6-methylmercaptopurine metabolites in a single sample. J Chromatogr 1992;583:83-90.
58. Krynetski EY, Krynetskaia NF, Yanishevski Y, Evans WE: Methylation of mercaptopurine, thioguanine, and their nucleotide metabolites by heterologously expressed human thiopurine S-methyltransferase. Mol Pharmacol 1995;47: 1141-1147.
59. Medard Y, Nafa S, Jacqz-Aigrain E: Thiopurine methyltransferase activity: New high-performance liquid chromatographic assay conditions. J Chromatogr [B] 1997;700:275-277.
60. Micheli V, Jacomelli G, Fioravanti A, Morozzi G, Marcolongo R, Pompucci G: Thiopurine methyltransferase activity in the erythrocytes of adults and children: and HPLC-linked assay. Clin Chim Acta 1997;259:161-168.
61. Kroplin T, Weyer N, Gutsche S, Iven H: Thiopurine S-methyltransferase activity in human erythrocytes: A new HPLC method using 6-thioguanine as substrate. Eur J Clin Pharmacol 1998;54:265-271.
62. Kroplin T, Fischer C, Iven H: Inhibition of thiopurine S-methyltransferase activity by impurities in commercially available substrates: A factor for differing results of TPMT measurements. Eur J Clin Pharmacol 1999;55:285-291.
63. Ameyaw MM, Collie-Duguid ES, Powrie RH, Ofori-Adjei D, McLeod HL: Thiopurine methyltransferase alleles in British and Ghanaian popultations. Hum Mol Genet 1999;8:367-370.
64. Alves S, Prata MJ, Ferreira F, Amorim A: Thiopurine methyltransferase pharmacogenetics: Alternative molecular diagnosis and preliminary data from Northern Portugal. Pharmacogenetics 1999;9:257-261.
65. Andersen JB, Szumlanski C, Weinshilboum RM, Schmiegelow K: Pharmacokinetics, dose adjustments, and 6-mercaptopurine/methotrexate drug interactions in two patients with thiopurine methyltransferase deficiency. Acta Paediatrica 1998;87:108-111.
66. Black AJ, McLeod HL, Capell HA, Powrie RH, Matowe LK, Pritchard SC, Collie-Duguid ES, Reid DM: Thiopurine methyltransferase genotype predicts therapy-limiting severe toxicity from azathioprine. Ann Intern Med 1998;129: 716-718.
67. Scerri L: Azathioprine in dermatological practice: An overview with special emphasis on its use in non-bullous inflammatory dermatoses. Adv Exp Med Biol 1999;455:343-348.
68. Relling MV, Hancock ML, Rivera GK, Sandlund JT, Ribeiro RC, Krynetski EY, Pui CH, Evans WE: Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus (see comments). J Natl Cancer Inst 1999;91:2001-2008.
69. McLeod HL, Krynetski EY, Relling MV, Evans WE: Genetic polymorphism of thiopurine methyltransferase and its clinical relevance for childhood acute lymphoblastic leukemia. Leukemia 2000;14:567-572.
70. Naughton MA, Battaglia E, O'Brien S, Walport MJ, Botto M: Identification of thiopurine methyltransferase (TPMT) polymorphisms cannot predict myelosuppression in systemic lupus erythematosus patients taking azathioprine. Rheumatology (Oxford) 1999;38:640-644.
71. Lysaa RA, Sylte I, Aarbakke J: A three dimensional model of human thiopurine methyltransferase: Ligand interactions and structural consequences of naturally occurring mutations. J Mol Modeling 1998;4:211-220.
72. Fields S: The future is function (news). Nat Genet 1997;15:325-327.